S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
NASDAQ:CARA

Cara Therapeutics (CARA) Stock Forecast, Price & News

$1.68
-0.11 (-6.15%)
(As of 02:52 PM ET)
Compare
Today's Range
$1.64
$1.86
50-Day Range
$1.67
$3.33
52-Week Range
$1.61
$12.81
Volume
557,285 shs
Average Volume
903,242 shs
Market Capitalization
$90.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Cara Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
911.9% Upside
$17.00 Price Target
Short Interest
Healthy
4.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.39
Upright™ Environmental Score
News Sentiment
0.55mentions of Cara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$13,222 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.93) to ($1.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

104th out of 963 stocks

Pharmaceutical Preparations Industry

33rd out of 451 stocks


CARA stock logo

About Cara Therapeutics (NASDAQ:CARA) Stock

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

CARA Price History

CARA Stock News Headlines

Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
6 Analysts Have This to Say About Cara Therapeutics
Q2 2023 Cara Therapeutics Inc Earnings Call
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Cara Therapeutics (NASDAQ: CARA)
See More Headlines
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Company Calendar

Last Earnings
8/07/2023
Today
9/27/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARA
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+918.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-85,470,000.00
Net Margins
-410.95%
Pretax Margin
-410.95%

Debt

Sales & Book Value

Annual Sales
$41.87 million
Book Value
$2.95 per share

Miscellaneous

Free Float
51,807,000
Market Cap
$90.31 million
Optionable
Optionable
Beta
0.87
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Christopher A. PosnerMr. Christopher A. Posner (Age 53)
    Pres, CEO & Director
    Comp: $1.2M
  • Mr. Ryan D. Maynard (Age 54)
    Chief Financial Officer
    Comp: $511.7k
  • Dr. Joana Goncalves M.D. (Age 49)
    Chief Medical Officer
    Comp: $747.25k
  • Dr. Derek T. Chalmers D.Sc. (Age 59)
    Ph.D., Co-Founder & Sr. Advisor
  • Dr. Frédérique Menzaghi (Age 57)
    Chief Scientific Officer and Sr. VP of R&D
  • Dr. Iris Francesconi Ph.D.
    Chief Strategy Officer & Head of Investor Relations
  • Mr. Scott M. TerrillionMr. Scott M. Terrillion (Age 60)
    Chief Compliance Officer, Gen. Counsel & Corp. Sec.
  • Mr. Eric Vandal
    Sr. VP of Commercial
  • Ms. Beth Weinberg R.Ph.
    Sr. VP of Regulatory Affairs & QA
  • Mr. Matthew Murphy
    Mang. of Investor Relations













CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CARA shares.
View CARA analyst ratings
or view top-rated stocks.

What is Cara Therapeutics' stock price forecast for 2023?

6 analysts have issued 12 month target prices for Cara Therapeutics' stock. Their CARA share price forecasts range from $4.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 918.0% from the stock's current price.
View analysts price targets for CARA
or view top-rated stocks among Wall Street analysts.

How have CARA shares performed in 2023?

Cara Therapeutics' stock was trading at $10.74 at the beginning of the year. Since then, CARA stock has decreased by 84.5% and is now trading at $1.67.
View the best growth stocks for 2023 here
.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,240,000 shares, an increase of 44.5% from the August 31st total of 1,550,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 5.0% of the shares of the company are sold short.
View Cara Therapeutics' Short Interest
.

When is Cara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our CARA earnings forecast
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) announced its quarterly earnings data on Monday, August, 7th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.02. The biopharmaceutical company had revenue of $6.93 million for the quarter, compared to analyst estimates of $6.49 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 75.82% and a negative net margin of 410.95%.

What ETF holds Cara Therapeutics' stock ?

Amplify Seymour Cannabis ETF holds 161,542 shares of CARA stock, representing 1.93% of its portfolio.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.85%), Clearbridge Investments LLC (1.85%), Bain Capital Life Sciences Investors LLC (1.73%), Geode Capital Management LLC (1.73%), State Street Corp (1.70%) and Pinnacle Associates Ltd. (1.25%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends
.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $1.67.

How much money does Cara Therapeutics make?

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $90.31 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

How many employees does Cara Therapeutics have?

The company employs 106 workers across the globe.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -